These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Questionnaire to assess quality of life in patients with breast cancer - Validation of the Chinese version of the EORTC QLQ-BR 53. Author: Zhang Z, Zhang X, Wei L, Lin Y, Wu D, Xie S, Yue L, Tian J, Zhang Y, Song Q, Woo SM, Miller AR, Luo L, Zhang L. Journal: Breast; 2017 Apr; 32():87-92. PubMed ID: 28068605. Abstract: PURPOSE: To evaluate the reliability and validity of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer (EORTC QLQ-BR53) questionnaire firstly in north of China. METHODS: A total of 294 outpatients with breast cancer in Tianjin Cancer Institution and Hospital from November 2014 to August 2015 were enrolled in this study. All patients self-administered the EORTC QLQ-BR25 and the Short Form 36 Health Survey (SF-36). The Eastern Cooperative Oncology Group (ECOG) scoring was performed to evaluate scores. Internal consistency reliability was determined by Cronbach's α coefficient for each dimension, with a Cronbach's α coefficient ≥0.7 considered to be statistically significant. RESULTS: A satisfactory internal consistency reliability for most multi-item scales was confirmed, as Cronbach's α coefficients were close or greater than 0.7 except for breast symptoms (0.615). Multiple-trait scaling analysis demonstrated a good convergent and divergent validity of EORTC QLQ-BR53. Using SF-36 as a reference standard to evaluate the dimensions of EORTC QLQ-BR53, most items in EORTC QLQ-BR53 possessed a favorable correlation with its own dimension (r > 0.4). A statistically significant difference was discovered in dimension scores between patients grouped by ECOG scores except for individual dimensions. CONCLUSIONS: The Chinese version of EORTC QLQ-BR53 is a reliable and valid instrument for measuring the quality of life among Chinese patients with breast cancer.[Abstract] [Full Text] [Related] [New Search]